Significance of nuclear factor - kappa beta activation on prostate needle biopsy samples in the evaluation of Gleason score 6 prostatic carcinoma indolence

Figure 1

Figure 2

Figure 3

Nuclear factor-kappa beta (NF-κB) p65 expression status in biopsy group GS 6 and control biopsy group GS 7

	N	NF-κB p65 expression		P
		negative	positive
3+3=6	123	103	20
3+4=7	30	24	6	0.596*
4+3=7	30	17	13	0.003**

Multivariate analysis of nuclear factor-kappa beta (NF-κB) p65 expression and other clinicopathologic variables associated with recurrence-free survival (RFS; recurrence defined as PSA ≥ 0_05)

	Hazard ratio (95% CI)	P
NF-(negative κB p65 expression vs. positive)	0.254 (0.034–1.915)	0.184
Postoperative score (6 vs. 7) Gleason	1.078 (0.400–2.907)	0.882
Surgical (negative margin vs. positive)	4.838 (1.674–13.983)	0.004
Pathologic (T2 vs. T3) stage	1.232 (0.409–3.705)	0.711

Association of nuclear factor-kappa beta (NF-κB) p65 expression status in cytoplasm with pathological findings

N = 123	N	NF-κB p65 expression		P
		negative	positive
pT status
pT2	96	48	48
pT3	27	12	15	0.667*
Surg. m.
Negative	110	53	7
Positive	13	7	6	0.774**
GS
3 + 3 = 6	79	39	40
3 + 4 = 7	37	17	20
4 + 3 = 7	7	5	2	0.465***

Association of nuclear factor-kappa beta (NF-κB) p65 expression status in nucleus with pathological findings

N = 123	N	NF-κB p65 expression		P
		negative	positive
pT status
pT2	96	81	15
pT3	27	22	5	0.769*
Surg. m.
Negative	110	92	18
Positive	13	11	2	1**
GS
3 + 3 = 6	79	66	13
3 + 4 = 7	37	31	6
4 + 3 = 7	7	6	1	0.989***

Multivariate analysis of cytoplasmic nuclear factor-kappa beta (NF-κB) p65 expression and other clinicopathologic variables associated with recurrence-free survival (RFS)

	Hazard ratio (95% CI)	P
Cytoplasmic NF-κB p65 expression (negative vs. positive)	2.367 (0.908–6.170)	0.078
Postoperative Gleason score (6 vs. 7)	1.105 (0.406–3.008)	0.845
Surgical (negative margin vs. positive)	4.845 (1.646–14.260)	0.004
Pathologic (T2 vs. T3) stage	1.041 (0.339–3.194)	0.944

Cytoplasmic nuclera factor-kappa beta (NF-κB) p65 expression status in biopsy group postoperative Gleason score (GS) 6 and control biopsy group postoperative GS 7

	N	NF-κB p65 expression		P
		negative	positive
3 + 3 = 6	123	60	63
3 + 4 = 7	30	3	27	<0.001*
4 + 3 = 7	30	0	30	<0.001**

Patient characteristics

General, N = 123
Mean Age, year, (range)		63.6 (50–75)
Mean init. PSA, ng/ml, (range)		5.32 (1,32–9,51)
Mean Prostate V, ml, (range)		38.3 (14–97)
Mean Biopsy cores, n, (range)		9.6 (8–10)
Total Biopsy cores, n		1.180
Clinical stage
T1, n, (%)		113 (91.9)
T2, n, (%)		10 (8.1)
Biopsy GS 3+3=6, n, (%)		123 (100)
Surgery
ELRP, n, (%)		87 (70.7)
N-S ELRP, n, (%)		36 (29.3)